Supernus Pharmaceuticals
Yahoo Finance • 2 days ago
BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; Investors Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm’s Investigation
BOSTON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) for potential securities law violations. Investors who have lost money in their Supernus Pharmaceuticals, Inc. inves... Full story
Yahoo Finance • 2 days ago
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial On Tuesday, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with trea... Full story
Yahoo Finance • 3 days ago
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated with few adverse events, consistent with... Full story
Yahoo Finance • 10 days ago
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
ROCKVILLE, Md., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, t... Full story
Yahoo Finance • 17 days ago
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wearable subcutaneous infusion device that provides continuous treatment du... Full story
Yahoo Finance • 4 months ago
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
Supernus Pharmaceuticals, Inc. ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central ne... Full story
Yahoo Finance • 9 months ago
Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.31 in 1Q 2023)
Supernus Pharmaceuticals (NASDAQ:SUPN) First Quarter 2024 Results Key Financial Results Revenue: US$143.6m (down 6.6% from 1Q 2023). Net income: US$124.0k (down 99% from 1Q 2023). Profit margin: 0.1% (down from 11% in 1Q 2023). EPS: US$0... Full story
Yahoo Finance • last year
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 8.7% CAGR over the last three years
It hasn't been the best quarter for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shareholders, since the share price has fallen 13% in that time. But that doesn't change the fact that the returns over the last three years have been pleasin... Full story
Yahoo Finance • last year
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript November 8, 2023 Supernus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.24, expectations were $0.13. Operator: Good afternoon, and welc... Full story
Yahoo Finance • last year
Supernus Announces Third Quarter 2023 Financial Results
Raises full year 2023 adjusted operating earnings (non-GAAP)(1) guidance range to $95 million to $110 million from previous range of $75 million to $100 millionTotal revenues (GAAP) of $153.9 million in the third quarter of 2023; total rev... Full story
Yahoo Finance • last year
Supernus to Participate in the Jefferies London Healthcare Conference
ROCKVILLE, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, a... Full story
Yahoo Finance • last year
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
ROCKVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, t... Full story
Yahoo Finance • last year
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
ROCKVILLE, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, t... Full story
Yahoo Finance • last year
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
ROCKVILLE, Md., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, t... Full story
Yahoo Finance • last year
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases,... Full story
Yahoo Finance • last year
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
Topline results from Phase IV study demonstrate Qelbree is safe and well-tolerated, and significantly improved efficacy outcomes when added to a stimulant medication in pediatric patients with ADHDFinal long-term data show Qelbree consiste... Full story
Yahoo Finance • last year
Supernus to Participate in the Wells Fargo Healthcare Conference
ROCKVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, a... Full story
Yahoo Finance • 2 years ago
Bethany L. Sensenig Joins Supernus’ Board of Directors
ROCKVILLE, Md., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, a... Full story
Yahoo Finance • 2 years ago
Supernus Announces First Quarter 2023 Financial Results
First quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 Qelbree® net product sales of $25.8 million, compared to $8.3 million in first quarter 2022GOCOVRI® net product sales of $26.0 million,... Full story
Yahoo Finance • 2 years ago
Supernus Announces Repayment of Convertible Notes
ROCKVILLE, Md., April 03, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases,... Full story
